PDCD1 and gastric cancer: Recently, a Phase II clinical study evaluated the combination of DKN‐01 with tislelizumab (a PD‐1 monoclonal antibody) and chemotherapy as a first‐line treatment for advanced GC/GEJC, yielding promising results.